Research Analysts Set Expectations for MAZE FY2024 Earnings

Maze Therapeutics, Inc. (NASDAQ:MAZE) – Analysts at Leerink Partnrs issued their FY2024 EPS estimates for Maze Therapeutics in a research note issued to investors on Tuesday, February 25th. Leerink Partnrs analyst J. Schwartz expects that the company will post earnings of ($4.93) per share for the year. Leerink Partnrs has a “Strong-Buy” rating on the stock. Leerink Partnrs also issued estimates for Maze Therapeutics’ Q4 2024 earnings at ($7.60) EPS, Q1 2025 earnings at ($0.58) EPS, Q2 2025 earnings at ($0.30) EPS, Q3 2025 earnings at ($0.59) EPS, Q4 2025 earnings at ($0.60) EPS, FY2025 earnings at ($2.07) EPS, FY2026 earnings at ($2.63) EPS, FY2027 earnings at ($2.52) EPS, FY2028 earnings at ($2.72) EPS and FY2029 earnings at ($3.17) EPS.

Several other analysts also recently commented on the stock. TD Cowen raised shares of Maze Therapeutics to a “strong-buy” rating in a research report on Tuesday. Guggenheim assumed coverage on shares of Maze Therapeutics in a report on Tuesday. They set a “buy” rating and a $19.00 price objective for the company. Leerink Partners assumed coverage on shares of Maze Therapeutics in a report on Tuesday. They set an “outperform” rating and a $28.00 price objective for the company. Finally, JPMorgan Chase & Co. assumed coverage on shares of Maze Therapeutics in a report on Tuesday. They set an “overweight” rating and a $30.00 price objective for the company. Three equities research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Buy” and a consensus price target of $25.67.

Maze Therapeutics Trading Down 3.9 %

MAZE stock opened at $12.23 on Thursday. Maze Therapeutics has a 12 month low of $10.08 and a 12 month high of $17.00.

Maze Therapeutics Company Profile

We are a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with renal, cardiovascular and related metabolic diseases, including obesity. We are advancing a pipeline using our Compass platform, which allows us to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process we refer to as variant functionalization.